santafescribbler
New member
U.S. Senator Pete Domenici (R-NM) Calls Effort Promising for State's Economy
Santa Fe, NM ? July 19, 2006 ? CytoDyn, Inc. (OTCBB: CYDY) has licensed
an extensive portfolio of patents and entered into certain sponsored
research agreements to add DNA plasmids to its product-development
pipeline. Over the past decade, DNA plasmids have been intensively
studied by academic institutions and have been characterized in the
literature as a potential breakthrough in fighting influenza (the flu).
CytoDyn, which is headquartered in New Mexico, plans to eventually
manufacture its entire drug pipeline in that State and has been in discussions with Kirtland Technology Park in Albuquerque, NM as a preferred site.
?This has the potential to be very promising for New Mexico?s economy
and our national quest to improve global preparedness against a
pandemic,? according to Senator Pete Domenici (R-NM). ?New Mexico is one
of the best places in the world for biotechnology R&D, and I believe it
will be an environment conducive for the success of CytoDyn. I am
pleased the firm intends to manufacture its product at Kirtland
Technology Park, which will add to the economic diversity our State
needs,? added Domenici who serves on the Senate Homeland Security and
Governmental Affairs Committee.
?Because the flu virus keeps changing as it jumps back and forth between
birds and mammals, new vaccines must continually be created,? according
to CytoDyn?s CEO Allen D. Allen. Given the limited infrastructure for
manufacturing vaccines, and the possibility of problems occurring at
various points along the complex delivery stream, shortages of vaccines
remain a persistent possibility. For the same reason, it is difficult to
stockpile a sufficient supply of vaccine for potential public-health
emergencies.
Results from clinical studies suggest that the H5N1 ?bird flu? vaccine
produced for the National Institute of Allergies and Infectious Diseases
could require a dose that is an order of magnitude higher.
?CytoDyn hopes to maintain adequate supplies of influenza vaccines by
developing a polyvalent line of DNA-based primers that could make the
vaccines more potent, thereby requiring a smaller dose in each flu shot
and extending the reach of the available supply,? Allen explained. For
more detailed information and tutorials on vaccines and the flu, please
visit our web site at www.cytodyn.com where you will also find helpful
links to other public and private sources of information.
Disclaimers
DNA plasmids are still in pre-clinical development, and there is no
guarantee that a safe and effective product can be developed. Even if
such a product were successfully developed, mutations of the virus or
other factors could render the product of little or no economic value.
Forward-looking statements are statements that are not historical facts.
The Company's management makes forward looking statements concerning the
Company's expected future operations, performance and other
developments. These forward-looking statements are necessarily estimates
based upon current information and involve a number of risks and
uncertainties. There can be no assurance that such risks and
uncertainties, or other factors, will not affect the accuracy of such
forward-looking statements. It is impossible to identify all factors
that could cause actual results to differ materially from those
estimated by the Company. They include, but are not limited to,
government regulation, managing and maintaining growth, victimization by
white-collar offenders, and the effects of adverse publicity,
litigation, competition, and other factors that may be identified from
time to time in the Company's announcements.
Source:
CytoDyn, Inc.
Santa Fe, NM ? July 19, 2006 ? CytoDyn, Inc. (OTCBB: CYDY) has licensed
an extensive portfolio of patents and entered into certain sponsored
research agreements to add DNA plasmids to its product-development
pipeline. Over the past decade, DNA plasmids have been intensively
studied by academic institutions and have been characterized in the
literature as a potential breakthrough in fighting influenza (the flu).
CytoDyn, which is headquartered in New Mexico, plans to eventually
manufacture its entire drug pipeline in that State and has been in discussions with Kirtland Technology Park in Albuquerque, NM as a preferred site.
?This has the potential to be very promising for New Mexico?s economy
and our national quest to improve global preparedness against a
pandemic,? according to Senator Pete Domenici (R-NM). ?New Mexico is one
of the best places in the world for biotechnology R&D, and I believe it
will be an environment conducive for the success of CytoDyn. I am
pleased the firm intends to manufacture its product at Kirtland
Technology Park, which will add to the economic diversity our State
needs,? added Domenici who serves on the Senate Homeland Security and
Governmental Affairs Committee.
?Because the flu virus keeps changing as it jumps back and forth between
birds and mammals, new vaccines must continually be created,? according
to CytoDyn?s CEO Allen D. Allen. Given the limited infrastructure for
manufacturing vaccines, and the possibility of problems occurring at
various points along the complex delivery stream, shortages of vaccines
remain a persistent possibility. For the same reason, it is difficult to
stockpile a sufficient supply of vaccine for potential public-health
emergencies.
Results from clinical studies suggest that the H5N1 ?bird flu? vaccine
produced for the National Institute of Allergies and Infectious Diseases
could require a dose that is an order of magnitude higher.
?CytoDyn hopes to maintain adequate supplies of influenza vaccines by
developing a polyvalent line of DNA-based primers that could make the
vaccines more potent, thereby requiring a smaller dose in each flu shot
and extending the reach of the available supply,? Allen explained. For
more detailed information and tutorials on vaccines and the flu, please
visit our web site at www.cytodyn.com where you will also find helpful
links to other public and private sources of information.
Disclaimers
DNA plasmids are still in pre-clinical development, and there is no
guarantee that a safe and effective product can be developed. Even if
such a product were successfully developed, mutations of the virus or
other factors could render the product of little or no economic value.
Forward-looking statements are statements that are not historical facts.
The Company's management makes forward looking statements concerning the
Company's expected future operations, performance and other
developments. These forward-looking statements are necessarily estimates
based upon current information and involve a number of risks and
uncertainties. There can be no assurance that such risks and
uncertainties, or other factors, will not affect the accuracy of such
forward-looking statements. It is impossible to identify all factors
that could cause actual results to differ materially from those
estimated by the Company. They include, but are not limited to,
government regulation, managing and maintaining growth, victimization by
white-collar offenders, and the effects of adverse publicity,
litigation, competition, and other factors that may be identified from
time to time in the Company's announcements.
Source:
CytoDyn, Inc.